Drugs / Ezetimibe/Rosuvastatin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04158076 | Jan 2020 → Jan 2021 | essential hypertension, hyperlipoproteinemia | Addpharma Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ezetimibe/Rosuvastatin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04158076 ↗ |
| Route | Oral | “PO, Once daily(QD), 8weeks” NCT04158076 ↗ |